Lin, Li <br/><br/>
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].  [electronic resource] 

 -  Zhonghua zhong liu za zhi [Chinese journal of oncology]  Oct 2010 
 - 786-90 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0253-3766 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--blood<br/>Adenocarcinoma, Mucinous--blood<br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--adverse effects<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>CA-19-9 Antigen--blood<br/>Camptothecin--administration & dosage<br/>Carcinoembryonic Antigen--blood<br/>Colonic Neoplasms--blood<br/>Diarrhea--chemically induced<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Hypertension--chemically induced<br/>Irinotecan<br/>Leucovorin--therapeutic use<br/>Male<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Rectal Neoplasms--blood<br/>Remission Induction<br/>Retrospective Studies<br/>Survival Rate<br/>Young Adult